New eczema drug goes head-to-head with dupixent in major trial
NCT ID NCT07386743
First seen Feb 04, 2026 · Last updated May 21, 2026 · Updated 8 times
Summary
This study compares a new medicine called GS101 to the existing drug Dupixent for people with moderate-to-severe atopic dermatitis (eczema). About 572 adults will receive either GS101 or Dupixent to see which works better at clearing skin and reducing itch. The main goal is to measure how many patients achieve at least a 75% improvement in eczema symptoms after 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.